Bristol Myers's most recent trend suggests a bullish bias. One trading opportunity on Bristol Myers is a Bull Put Spread using a strike $52.50 short put and a strike $47.00 long put offers a potential 9.78% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $52.50 by expiration. The full premium credit of $0.49 would be kept by the premium seller. The risk of $5.01 would be incurred if the stock dropped below the $47.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Bristol Myers is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin)
Wed, 08 Jan 2014 22:53:46 GMT
noodls – Dateline: WILMINGTON, Del. & PRINCETON, N.J. WILMINGTON, Del. & PRINCETON, N.J.–(BUSINESS WIRE)–AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug …
7:01 am Bristol-Myers receives Marketing Authorization Application for Daclatasvir for treatment of chronic Hepatitis C; validated for accelerated regulatory review by the EMA
Wed, 08 Jan 2014 22:42:27 GMT
Briefing.com – 7:01 am Bristol-Myers receives Marketing Authorization Application for Daclatasvir for treatment of chronic Hepatitis C; validated for accelerated regulatory review by the EMA
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin)
Wed, 08 Jan 2014 22:06:00 GMT
Business Wire – AstraZeneca and Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration has approved Farxiga™ .
Why Obamacare and Hospira Inc. Are The Perfect Fit
Wed, 08 Jan 2014 21:54:13 GMT
Motley Fool – … and why Hospira Inc. looks like a solid investment.
“Star Trek” Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods
Wed, 08 Jan 2014 18:25:25 GMT
Motley Fool – The next-generation of cancer-fighting agents could be right around the corner.
Related Posts
Also on Market Tamer…
Follow Us on Facebook